methylprednisolone - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.91 [0.29, 2.86]< 10%1 study (2/-)56.4 %NAnot evaluable crucial-
deaths (time to event analysis only) 0.29 [0.15, 0.56]< 10%1 study (1/-)100.0 %NAnot evaluable crucial-
clinical improvement 12.00 [2.39, 60.20]> 10%1 study (1/-)99.9 %NAnot evaluable important-

safety endpoints 00

serious adverse events 0.81 [0.11, 6.17]< 10%1 study (1/-)57.9 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.